{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000125","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.920696+00:00","generated_at":"2026-06-10T07:07:56.315985+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xeris Biopharma exchanges $32M of 5% convertible notes for $33.6M of new 8% notes due 2028","bullets":["Exchanged $31,975,000 of 5% Convertible Senior Notes due 2025 for $33,574,000 of new 8.00% Convertible Senior Notes due 2028.","New notes bear 8.00% interest, payable semi-annually; maturity July 15, 2028.","Initial conversion rate is 326.7974 shares per $1,000 principal, implying ~$3.06 per share.","Notes are senior unsecured, guaranteed by Xeris Pharmaceuticals, issued to QIBs via Section 4(a)(2) exemption.","Company may redeem notes after July 20, 2026 if stock price exceeds 130% of conversion price for 20 of 30 trading days."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000125","json":"https://secwatch.observer/filing/0001867096-23-000125.json","markdown":"https://secwatch.observer/filing/0001867096-23-000125.md","text":"https://secwatch.observer/filing/0001867096-23-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/0001867096-23-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/xers-20230929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:07:56.315985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dab9a4290474a8c2dd0ef382aa525dd884164ce","claim":"Xeris Biopharma Holdings, Inc. incurred convertible notes of $33,574,000 with qualified institutional buyers at 8.00% per annum maturing July 15, 2028.","evidence_excerpt":"Xeris Biopharma Holdings, Inc., a Delaware corporation (the “ Company ”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the “ Guarantor ”), closed the previously announced exchange of $31,975,000 in aggregate principal amount of the Guarantor’s 5.00% Convertible Senior Notes due 2025 (the “ Existing Notes ”) for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the “ New Notes ”) (the “ Exchange Transactions ”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/0001867096-23-000125-index.htm","confidence":0.97,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$33,574,000"},{"label":"Counterparty","value":"qualified institutional buyers"},{"label":"Rate","value":"8.00% per annum"},{"label":"Maturity","value":"July 15, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"0a33fd6fb6ff98a0dbd7f6fac84bb33af7de55b6","claim":"Xeris Biopharma Holdings, Inc. entered into Indenture for 8.00% Convertible Senior Notes due 2028 with U.S. Bank Trust Company, National Association valued at $33,574,000 in aggregate principal amount of 8.00% Convertible Senior Notes due 2028 (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, Xeris Biopharma Holdings, Inc., a Delaware corporation (the \" Company \"), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the \" Guarantor \"), closed the previously announced exchange of $31,975,000 in aggregate principal amount of the Guarantor’s 5.00% Convertible Senior Notes due 2025 (the \" Existing Notes \") for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the \" New Notes \") (the \" Exchange Transactions \"), in each case, pursuant to the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the \" Securities Act \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/0001867096-23-000125-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Value","value":"$33,574,000 in aggregate principal amount of 8.00% Convertible Senior Notes due 2028"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}